Key Takeaways

  • McLerran & Associates surfaces governance defects such as 50/50 deadlock and missing tiebreaker mechanisms during diligence, before they become deal-breakers at buyout.
  • Regulatory exposure under Stark, the Anti-Kickback Statute, state Corporate Practice of Dentistry doctrine, and HIPAA can reduce exit value or stall a sale when unresolved compliance issues surface in buyer diligence.
  • Unequal production paired with equal profit splits creates resentment and depresses sale value because buyers price in the resulting partnership instability.
  • Buy-sell valuation disputes arise when formulas fail to account for outstanding debt, goodwill discounts, accounts-receivable treatment, and installment-payment terms, all of which directly affect the net proceeds a departing partner receives.
  • McLerran & Associates produces side-by-side private-buyer and DSO valuations and runs a structured bid process that converts partnership defects into quantified dollar outcomes before any agreement is signed.

Talk With McLerran & Associates About Your Partnership

Common Legal Issues in Dental Partnerships

Flawed Or Missing Partnership Agreements And Deadlock

A 50/50 ownership split with no tiebreaker mechanism can be one of the most common avoidable structural errors in dental partnerships. The structure functions without friction until the first serious disagreement, for example, two equal partners deadlocked over a $150,000 equipment purchase. At that point, the partnership may have no exit except litigation or a forced sale.

Deadlock-resolution mechanisms can include an uneven 51/49 split, a named independent neutral party for defined dispute categories, mandatory mediation followed by arbitration, or a shotgun or buy-sell trigger in which one partner names a price and the other must buy or sell at it. A shotgun trigger favors the partner with greater access to capital, because that partner can name a low price knowing the other cannot afford to buy at it. At exit, buyers discount practices with governance paralysis, and unresolved deadlock can delay or kill a sale entirely.

McLerran & Associates’ transition process surfaces these governance defects during diligence before they become deal-breakers. For a deeper look at governance structures, see McLerran & Associates’ guide to dental partnership governance and decision making.

McLerran & Associates team: McLerran is the nation's largest dental-specific sell-side M&A advisory and brokerage firms
McLerran & Associates team: McLerran is the nation's largest dental-specific sell-side M&A advisory and brokerage firms

Regulatory Exposure: Stark, Anti-Kickback, Corporate Practice of Dentistry, HIPAA

Governance defects are the structural risk, and compliance defects are the regulatory risk. Four regulatory frameworks can intersect in a dental partnership.

The Stark Act (42 U.S.C. § 1395nn, implemented at 42 C.F.R. § 411.353) prohibits a physician with a financial relationship with a designated health services entity from making Medicare referrals to that entity unless a specific exception applies. A partnership interest or profit distribution can constitute such a financial relationship, and the analysis cannot be skipped simply because partners share ownership equally.

Critically, 42 C.F.R. § 411.350(b) expressly states that the Stark subpart does not provide exceptions or immunity from civil or criminal prosecution or other sanctions under any state law or under federal law other than section 1877, naming HHS, the FTC, the SEC, the IRS, and other federal or state agencies. A Stark-compliant arrangement can still violate those parallel frameworks.

HIPAA obligations depend on whether the partnership qualifies as a single covered entity, affiliated covered entities, or separate entities. Shared systems, cloud vendors, and departing-partner record access can each create unauthorized-use, minimum-necessary, and security-rule exposure that the partnership agreement and buy-sell transition provisions should address. State law varies on all of these dimensions, and counsel should confirm the structure in the applicable jurisdiction.

Unresolved compliance issues surface in diligence and can become price reductions or deal-breakers. McLerran & Associates’ dental-only focus means it reads these compliance dynamics as part of valuation and deal structure.

Restrictive Covenants And Exit Terms

Non-compete and non-solicitation enforceability now varies by state and is fragmenting rapidly. After a federal court blocked the FTC’s 2024 noncompete rule and the FTC dropped its appeal, noncompete regulation reverted entirely to the states.

California voids most non-competes under Business & Professions Code § 16600. Texas enacted SB 1318, effective September 1, 2025, which extends limits similar to physician non-competes to dentists, with reported caps of one year within a five-mile radius. Pennsylvania, Virginia, Montana, and several other states have moved to void or sharply limit covenants for healthcare practitioners, and Florida moved in the opposite direction with its 2025 CHOICE Act.

An unenforceable or overbroad covenant becomes a valuation and negotiation issue at buyout, because a buyer cannot safely assume the departing dentist will be barred from competing. That uncertainty reduces goodwill, patient-retention expectations, and the value assigned to the departing partner’s interest. State-specific review should occur both at drafting and again when a partner exits.

McLerran & Associates negotiates LOI terms and deal structures on the seller’s behalf, accounting for the enforceability landscape in the relevant state.

Common Financial Issues in Dental Partnerships

Unequal Production Versus Equal Profit Split

A dental partnership’s economics can be understood in four components: clinical production compensation tied to each partner’s output, management compensation for administrative duties, return on ownership proportional to equity, and residual profit distributions. When these components are blended into a single undifferentiated draw, the higher-producing partner subsidizes the lower-producing one.

Consider two 50/50 partners where one produces $900,000 and the other $600,000. Splitting all economics equally means the higher producer effectively transfers value to the lower producer every year. That resentment erodes trust, distracts both partners from growth, and depresses sale value, because buyers see instability and price it accordingly.

McLerran & Associates’ CPA-led EBITDA analysis (EBITDA stands for earnings before interest, taxes, depreciation, and amortization, a measure of true operating profitability) establishes what the practice actually earns before any split is negotiated. That baseline gives both partners a defensible starting point. See also McLerran & Associates’ resource on dental partnership ownership percentages for how equity stakes interact with compensation.

At McLerran & Associates, every engagement is built on an ironclad, CPA-led EBITDA analysis and practice valuation.
At McLerran & Associates, every engagement is built on an ironclad, CPA-led EBITDA analysis and practice valuation.

Buyout and Buy-Sell Valuation Disputes

Buy-sell provisions can be triggered by retirement, death, disability, voluntary departure, loss of license, or a practice sale. A common misconception is that a 50% interest in a $2 million practice automatically produces a $1 million check. That outcome rarely occurs.

Outstanding loans reduce equity value. Accounts receivable may or may not be included depending on the agreement’s language. Goodwill, the intangible value of patient relationships, systems, and reputation, is subject to valuation methodology and can be discounted for minority interest or lack of marketability. Lease obligations, equipment debt, and other liabilities all reduce the net proceeds a departing partner receives.

A buy-in formula that does not match the buy-out formula is one of the most common flashpoints in dental partnership disputes. Every legal and financial issue described in this article, including governance paralysis, regulatory exposure, unenforceable covenants, and unequal production, ultimately gets priced at this moment.

McLerran & Associates produces a side-by-side valuation quantifying a practice’s worth in both the private-buyer and DSO markets, so partners can see the economic outcome before signing a buy-sell. For a detailed look at the financial statements that support these valuations, see McLerran & Associates’ article on financial statement requirements for dental partnerships.

Personal Guarantees and Debt Allocation

One partner may sign a personal guarantee on a loan that benefits both partners, such as equipment financing, a build-out loan, or a practice acquisition note. On departure, the guarantor remains exposed while the remaining partner continues to benefit from the asset.

Personal guarantee exposure is frequently overlooked during partnership formation but becomes critical when practices take on debt for expansion or equipment. Agreements often fail to define who bears debt service before distributions are made, creating a second layer of dispute when one partner wants to exit.

Guarantees reduce the departing partner’s net proceeds and can stall a buyout if the lender requires the guarantor to remain on the note until the loan is retired. McLerran & Associates’ financial forecasting and cash-flow modeling quantifies after-tax proceeds across deal structures and time horizons, so a departing partner can see what a guarantee costs in net dollars before agreeing to any exit terms.

How These Issues Get Priced At Buyout And Sale

When a dental partnership reaches a transition, whether a partner departs, retires, becomes disabled, or the practice sells to a third party, every structural and financial defect described above gets converted into a dollar figure. Buyers and their advisors are experienced at this conversion.

Governance paralysis, such as a deadlock with no resolution mechanism, signals operational risk and reduces the multiple a buyer will pay. Unresolved regulatory exposure under Stark, the Anti-Kickback Statute, or state Corporate Practice of Dentistry doctrine surfaces in diligence and can become either a price reduction or a condition that must be remedied before closing. An unenforceable restrictive covenant reduces the goodwill value a buyer will assign, because goodwill assumes the departing dentist will not immediately compete for the same patients.

Unequal production with no documented compensation separation creates questions about whether the practice’s reported profitability is sustainable after a partner leaves. A personal guarantee that was never addressed in the partnership agreement becomes a negotiation point that can reduce net proceeds or delay closing.

What a partner actually receives at exit comes down to a short set of adjustments. Start with the practice’s enterprise value, usually a multiple of adjusted EBITDA or a percentage of collections. Subtract outstanding debt allocated to the departing partner’s interest and any minority-interest or marketability discounts. Accounts receivable may be added or excluded depending on the agreement’s language, and earnout, installment, or holdback terms can change the final number again.

Dental partnership buyout agreements commonly allow payment over five to ten years at a stated interest rate often pegged to prime plus one or two percentage points, because lump-sum buyouts are rare given how little cash most practices hold. The departing partner’s financial outcome therefore depends on the headline valuation and on the payment terms, interest rate, and security behind the installment obligation.

That translation from clause to dollar figure is where many advisors stop. McLerran & Associates builds the valuation and runs the bid process that turns each defect into a number a buyer will actually pay against. As a dental-only sell-side advisor with approximately 2,000 successful practice sales, roughly $2 billion in closed transaction volume, and a transaction rate of approximately 85–90% against an industry norm closer to 35–40%, the firm quantifies what partnership defects cost at exit.

A chat at McLerran & Associates: the dental-specific sell-side advisor and advocate for practice owners guides on how, when, and to whom to sell your practice.
A chat at McLerran & Associates: the dental-specific sell-side advisor and advocate for practice owners guides on how, when, and to whom to sell your practice.

McLerran & Associates’ structured, auction-like bid process typically generates around 10 offers within approximately 45–60 days, creating the competitive tension that holds valuation and protects terms through diligence. Consult your legal and tax advisors on the specific implications for your situation.

See What Your Partnership Is Worth at Exit

A Protections Checklist for Dental Partners

The following steps can help reduce the risk that common legal and financial issues in dental partnerships erode exit value. This checklist is educational in nature and is not a substitute for advice from qualified legal, tax, and financial advisors familiar with your specific situation and state law.

  • Have a dental attorney and a dental CPA review the partnership agreement, corporate documents, employment agreements, and loan documents together. Obligations in one document frequently conflict with or modify obligations in another.
  • Understand exit value before signing anything. A side-by-side private-buyer and DSO valuation shows what your interest is worth in both markets, so the decision rests on real numbers rather than assumptions.
  • Build deadlock-resolution and buy-sell triggers into the agreement, with funded life and disability coverage sized to the buyout obligation and reviewed periodically as practice value changes. Without funded buy-sell provisions, a partner’s death or disability can leave the surviving partner in business with the deceased’s estate or facing a buyout obligation with no cash to fund it.
  • Separate clinical compensation from profit distributions in writing. The partnership agreement should state explicitly that each partner’s production-based pay is distinct from ownership-based distributions, and that overhead allocation follows a defined, documented formula.
  • Obtain a diligence-grade valuation. McLerran & Associates’ CPA-led EBITDA analysis is built to hold up under buyer scrutiny, the kind of work that does not get re-traded when a buyer’s quality-of-earnings team reviews the numbers. For more on what a partnership agreement should contain to support this process, see McLerran & Associates’ resource on dental partnership operating agreement key terms.

Conclusion: The Clauses That Decide What Your Partnership Is Worth

Common legal and financial issues in dental partnerships shape what the partnership is worth when someone leaves or the practice sells. Specific clauses around governance, compensation, buyout mechanics, personal guarantees, and regulatory compliance can reduce exit value, delay a transaction, or convert a straightforward buyout into a dispute.

McLerran & Associates is a dental-specific sell-side advisory firm for dentists navigating these partnership issues. The firm has evaluated more than 10,000 practices, runs both private-buyer and DSO transition paths in roughly equal measure, and builds CPA-led, diligence-grade valuations that can hold up when partnership disputes reach buyout.

Current partners, associates with a written or promised buy-in, and sole owners weighing whether to add a partner all benefit from understanding value before signing agreements. The time to understand what your interest is worth, and what could reduce it, is before any agreement is signed.

To schedule a free, confidential discovery call with McLerran & Associates, call (512) 900-7989, email info@dentaltransitions.com, or visit the contact page below. If you have not yet decided whether a transition is right for you, the McLerran M&A Summit (October 29–30, 2026) is built for owners at exactly that stage, offering 4 CE credits and a complimentary practice valuation.

Discuss Your Partnership And Exit Options

Frequently Asked Questions

What Legal Issues Arise in a Dental Partnership?

Common legal issues in dental partnerships include flawed or missing partnership agreements, 50/50 ownership structures with no deadlock-resolution mechanism, regulatory exposure under the Stark Act, the federal Anti-Kickback Statute, state Corporate Practice of Dentistry doctrine, and HIPAA, and restrictive covenants that may be unenforceable under current state law. Buy-sell provisions, the sections of the agreement that govern what happens when a partner retires, becomes disabled, dies, or departs, can be some of the most consequential and most frequently deficient elements.

Without clear buyout terms, a partner’s exit can paralyze the practice or force a fire sale. State law varies significantly on entity structure, ownership restrictions, and non-compete enforceability, so a dental attorney familiar with the applicable jurisdiction should review the full set of governing documents together.

What Financial Issues Cause Dental Partner Disputes?

The most common financial issues in dental partnerships include unequal production with an equal profit split and no documented compensation separation, buyout valuation disputes arising from a formula that does not match the buy-in formula or that fails to account for outstanding debt and goodwill, and personal guarantees on practice loans that follow only one partner at departure.

A practice that blends clinical compensation and ownership distributions into a single undifferentiated draw creates the conditions for resentment and eventual dispute. Overhead allocation, meaning how fixed and variable costs are divided between partners, is another frequent flashpoint when it is not defined in writing. These financial misalignments can reduce sale value because buyers assess partnership stability as part of their underwriting.

What Happens When a Dental Partner Wants to Leave?

When a dental partner wants to leave, the buy-sell provisions of the partnership or operating agreement govern the process, including who may buy the departing partner’s interest, how the price is determined, when payment is due, and what continuing obligations the departing partner carries. A 50% interest in a practice does not automatically produce a payout equal to 50% of the practice’s gross value.

Outstanding loans, accounts receivable treatment, goodwill valuation methodology, minority-interest discounts, and installment payment terms all affect the net amount the departing partner receives. If the agreement is silent or ambiguous on any of these points, the departure can become a negotiation or a dispute. McLerran & Associates works with selling partners to establish real exit value before any buy-sell is signed, so the economic outcome is understood in advance rather than discovered at the moment of departure.

What Is a Red Flag in a Dental Partnership?

Several structural and financial features can signal elevated risk in a dental partnership. The 50/50 deadlock described earlier is the most commonly cited red flag, because it leaves litigation or a forced sale as the only exits from a serious disagreement.

A buyout formula that differs materially from the buy-in formula is another, because it means the price a partner paid to enter the partnership may bear little relationship to what they receive when they leave. Other red flags include a valuation formula controlled by one party or based on undefined accounting adjustments, personal guarantees that are not addressed in the partnership agreement, buy-sell provisions that are not funded with life and disability insurance, and restrictive covenants that have not been reviewed against current state law. Any of these can reduce exit value or convert a routine departure into a dispute.

How Are Dental Partnership Profits Split When Production Is Unequal?

Dental partnership compensation can be structured in several ways, including equal splits regardless of production, splits by ownership percentage, production- or collections-based pay where each partner receives a share of their own output, or hybrid arrangements that combine a production-based clinical component with an ownership-based distribution of residual profit.

When production is unequal and the agreement does not separate clinical compensation from profit distributions, the higher-producing partner effectively subsidizes the lower-producing one. A defensible approach is to document clinical compensation and profit distributions as separate formulas in the partnership agreement, with a defined overhead allocation method, so each partner’s total compensation reflects both their clinical contribution and their ownership stake. McLerran & Associates’ CPA-led EBITDA analysis establishes true practice profitability before any split is negotiated, giving partners a defensible baseline for these conversations.

How Does McLerran & Associates Help When Partnership Issues Reach Buyout?

McLerran & Associates serves as a dental-specific sell-side advisor and advocate for practice owners navigating the transition stage, including situations where partnership issues have created uncertainty about exit value. The firm’s process begins with a CPA-led, diligence-grade EBITDA analysis that establishes what the practice actually earns and what it is worth in both the private-buyer and DSO markets.

From that foundation, McLerran & Associates produces a side-by-side valuation and multi-year financial forecast so partners can see the economic outcome across deal structures and time horizons before signing anything. For practices that proceed to a sale, McLerran & Associates runs a structured, auction-like bid process among a vetted pool of buyers, negotiates LOI terms and deal structure on the seller’s behalf, and defends the valuation through diligence so the agreed value can hold at closing. The firm’s track record, cited earlier, is the reason that pricing can hold up under buyer scrutiny. Consult your legal and tax advisors regarding the specific implications for your situation.

What to Read Next

Get In Touch